- Home
- MCRB vs BMEA Comparison
MCRB vs BMEA Comparison
Compare MCRB & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- BMEA
- Stock Information
- Founded
- MCRB 2010
- BMEA 2017
- Country
- MCRB United States
- BMEA United States
- Employees
- MCRB N/A
- BMEA N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- BMEA Health Care
- Exchange
- MCRB Nasdaq
- BMEA Nasdaq
- Market Cap
- MCRB 144.6M
- BMEA 125.0M
- IPO Year
- MCRB 2015
- BMEA 2021
- Fundamental
- Price
- MCRB $20.76
- BMEA $1.75
- Analyst Decision
- MCRB Hold
- BMEA Strong Buy
- Analyst Count
- MCRB 4
- BMEA 8
- Target Price
- MCRB $14.33
- BMEA $10.63
- AVG Volume (30 Days)
- MCRB 227.9K
- BMEA 812.2K
- Earning Date
- MCRB 11-12-2025
- BMEA 10-28-2025
- Dividend Yield
- MCRB N/A
- BMEA N/A
- EPS Growth
- MCRB N/A
- BMEA N/A
- EPS
- MCRB 10.22
- BMEA N/A
- Revenue
- MCRB N/A
- BMEA N/A
- Revenue This Year
- MCRB N/A
- BMEA N/A
- Revenue Next Year
- MCRB N/A
- BMEA N/A
- P/E Ratio
- MCRB $2.05
- BMEA N/A
- Revenue Growth
- MCRB N/A
- BMEA N/A
- 52 Week Low
- MCRB $6.53
- BMEA $1.29
- 52 Week High
- MCRB $24.67
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- MCRB 59.57
- BMEA 42.68
- Support Level
- MCRB $19.14
- BMEA $1.98
- Resistance Level
- MCRB $21.97
- BMEA $2.99
- Average True Range (ATR)
- MCRB 1.52
- BMEA 0.19
- MACD
- MCRB 0.22
- BMEA -0.00
- Stochastic Oscillator
- MCRB 78.90
- BMEA 5.64
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.